TG Therapeutics, Inc. (TGTX) — ESG & Values Scores

Environment story

TGTX is a biopharmaceutical company with minimal disclosed environmental footprint data. No Scope 1, 2, or 3 emissions reporting identified in available filings. No net-zero target disclosed. The company operates primarily in drug development and commercialization, with limited manufacturing (outsourced). No major environmental controversies detected in provided documents. Absence of climate commitments and emissions disclosures results in moderate deductions; however, as a biotech firm without heavy industrial operations, baseline environmental risk is lower than manufacturing-intensive sectors.

Criticisms on file

No material criticisms on file for this pillar.

Disclosed initiatives

Outsourced Manufacturing Model

TGTX contracts third-party manufacturers for BRIUMVI and product candidates, reducing direct operational emissions footprint.

Indirect reduction of Scope 1&2 emissions; shifts responsibility to contract partners.

Social story

TGTX has limited disclosed social-responsibility infrastructure in the provided 10-K filing. No CEO-to-worker pay ratios, diversity metrics, or turnover data disclosed. No union activity or labor disputes documented. The 10-K emphasizes commercialization challenges, patient safety (BRIUMVI post-marketing studies, REMS programs), and healthcare access concerns regarding immunosuppressive therapies. The company acknowledges supply-chain risks related to global manufacturing and clinical trial operations but provides no formal supply-chain human-rights audits or living-wage commitments. Diversity and compensation equity programs are not mentioned, resulting in moderate deductions for undisclosed leadership diversity and absent formal social initiatives.

Criticisms on file

Immunosuppressive Product Safety Concerns: Patients and healthcare providers have raised concerns that anti-CD20 antibodies and B-cell targeted agents may increase risk of severe infections or death, potentially impacting BRIUMVI commercial acceptance.
Source: TGTX 10-K, Risk Factors – Commercialization section

Disclosed initiatives

Post-Marketing Safety Surveillance for BRIUMVI

Long-term safety studies, pregnancy/pediatric population studies, and Phase 4 observational studies (ENABLE real-world study) to monitor product safety and efficacy.

Protects patient safety; supports continuous monitoring of immunosuppressive therapy risks.
Clinical Trial Recruitment and Patient Access

Efforts to identify and recruit patients for clinical trials; managing patient eligibility and treatment access.

Ensures diverse patient populations participate in trials; addresses healthcare equity in MS treatment.

Governance story

TGTX governance structure not fully disclosed in provided 10-K excerpts. Board independence percentage, share structure details, and formal lobbying expenditures are not specified in the available risk-factor sections. The company operates under extensive FDA and regulatory oversight for drug development and commercialization, with post-approval commitments and REMS programs indicating regulatory responsiveness. No antitrust or major consumer-fraud proceedings mentioned. The company has entered into a $250 million term loan (August 2024) with Blue Owl Capital, which imposes restrictive covenants limiting asset disposal, business changes, M&A, additional debt, asset liens, dividends, and affiliate transactions. Debt covenants and collateral securitization may constrain governance flexibility. No evidence of shareholder litigation or climate proposal blocking detected in provided materials.

Criticisms on file

Debt Covenant Restrictions: $250M term loan from Blue Owl Capital (August 2024) secured by substantially all company assets; restrictive covenants limit business flexibility including M&A, asset sales, additional debt, and capital allocation.
Source: TGTX 10-K, Note 7 – Loan Payable; Risk Factors – Financial Position section

Disclosed initiatives

Regulatory Compliance Infrastructure

Compliance with FDA cGMP, GCP, GLP; post-marketing surveillance programs; REMS program; adverse event reporting and pharmacovigilance systems.

Ensures ongoing regulatory compliance and product safety oversight.
Healthcare Compliance Program

Maintenance of mechanisms for compliance monitoring in commercialization operations.

Mitigates legal and reputational risk in healthcare sales and marketing.

These are Missionomics' own editorial scores — directional signals built from disclosed facts under a published method, not certifications or definitive ratings of TG Therapeutics, Inc.. Coverage and confidence vary by data point, and figures can lag real-world changes. Read the full Methodology for sourcing, scoring, and correction details — or open TG Therapeutics, Inc. in the app for interactive charts and portfolio building.

More in Healthcare

Eli Lilly and Company (LLY) Johnson & Johnson (JNJ) AbbVie Inc. (ABBV) UnitedHealth Group Incorporated (UNH) Merck & Co., Inc. (MRK) Thermo Fisher Scientific Inc. (TMO)